Cellular growth, dierentiation and migration is regulated by protein tyrosine phosphorylation. Receptor-like protein tyrosine phosphatases are thus likely to be key regulators of vital cellular processes. The regulation of these enzymes is in general poorly understood. 
Cellular growth, dierentiation and migration is regulated by protein tyrosine phosphorylation. Receptor-like protein tyrosine phosphatases are thus likely to be key regulators of vital cellular processes. The regulation of these enzymes is in general poorly understood. Ligands have been identi®ed only for a small subset of the receptor-like protein tyrosine phosphatases and in no case has upregulation of the speci®c activity by extracellular ligands been demonstrated. Prompted by earlier ®ndings of ligands for receptor-like protein tyrosine phosphatases in extracellular matrix we investigated if Matrigel TM , a preparation of extracellular matrix proteins, contained modulators of the speci®c activity of the receptor-like protein tyrosine phosphatase DEP-1. Matrigel TM stimulation of cells increased the speci®c activity of immunoprecipitated DEP-1. Also, incubation of immunoprecipitated DEP-1 with Matrigel TM led to an increase in DEP-1 activity, which was blocked by soluble DEP-1 extracellular domain. Finally, immunoprecipitated DECD-DEP-1, a mutant form of DEP-1 lacking most of the extracellular domain, failed to respond to Matrigel TM stimulation. These experiments identify Matrigel TM as a source of DEP-1 agonist(s) and provide the ®rst evidence for upregulation of the speci®c activity of receptor-like protein tyrosine phosphatases by extracellular ligands. Oncogene (2001) 20, 5219 ± 5224.
Keywords: DEP-1; Matrigel TM ; protein tyrosine phosphatase Tyrosine phosphorylation of proteins controls cellular growth, dierentiation and migration, and is regulated by the concerted action of kinases and phosphatases. The net tyrosine phosphorylation is thus determined by the expression levels, speci®c activities and localization of tyrosine kinases and protein tyrosine phosphatases (PTPs). Consequently, the regulation of PTPs constitutes a central biological control mechanism.
Receptor-like protein tyrosine phosphatases (rPTPs) are composed of an extracellular domain, a single transmembrane segment and one or two intracellular catalytic domains (Brady-Kalnay and Tonks, 1995; Van Vactor, 1998) . These structural features suggest that rPTPs are regulated by extracellular ligands. For most rPTPs the ligands remain uncharacterized. Known ligands for rPTPs include the extracellular domains of PTPm and PTPk, that act as homophilic ligands (Brady-Kalnay et al., 1993; Gebbink et al., 1993; Sap et al., 1994) , and contactin which interacts with PTPb/z and PTPa (Peles et al., 1995; Zeng et al., 1999) , as well as the extracellular matrix proteins tenascin and the laminin-nidogen complex which binds PTPb/z and LAR, respectively (Barnea et al., 1994 , O'Grady et al., 1998 . The recent observation of pleiotrophin-mediated inactivation of PTPb/z provided the ®rst evidence for regulation of rPTPs by extracellular ligands (Meng et al., 2000) . However, upregulation of speci®c activity by extracellular ligands has not yet been demonstrated for any rPTP.
The rPTP DEP-1, also designated PTPZ and CD148, is composed of eight ®bronectin type III repeats in its extracellular domain, and a single intracellular catalytic domain (Honda et al., 1994; O È stman et al., 1994) . Immunohistochemical stainings have revealed a broad tissue distribution of DEP-1; prominent expression was found in thymus, and also on many epithelial cell types with glandular or endocrine dierentiation (Autschbach et al., 1999) . DEP-1 expression is enhanced in high cell density cultures of ®broblasts and in contactinhibited endothelial cells (Borges et al., 1996; O È stman et al., 1994) , and heterologous expression of DEP-1 in bovine aortic endothelial cells leads to inhibition of cfos and Cyclin A promotor activity (Suzuki et al., 2000) . DEP-1 expression has also been shown to be upregulated after dierentiation of breast cancer cells (Keane et al., 1996) and thyroid cells (Martelli et al., 1998; Zhang et al., 1997) . Re-expression of DEP-1 in transformed thyroid cells suppress the transformed phenotype and leads to increased levels of cyclindependent kinase inhibitor p27 (Trapasso et al., 2000) . Recent studies have also indicated a role of DEP-1 in lymphocyte signal transduction (de la Fuente-GarcõÂ a et al., 1998; Tangye et al., 1998a,b) . The inhibitory eects of DEP-1 on T-cell receptor signaling are associated with reduced tyrosine phosphorylation of the adaptor protein LAT and of phospholipase Cg1 (Baker et al., 2001) . The physiological substrates of DEP-1 remain unknown. However, after transfection into plateletderived growth factor (PDGF) b-receptor expressing cells, DEP-1 mediates site-selective dephosphorylation of a subset of PDGF b-receptor autophosphorylation sites (Kovalenko et al., 2000) .
Prompted by earlier ®ndings of rPTP ligands in extracellular matrix we investigated if Matrigel TM , a preparation of extracellular matrix proteins, contained modulators of the speci®c activity of DEP-1.
X23 cells, i.e. porcine aortic endothelial (PAE) cells with tetracycline regulated expression of human DEP-1 with a carboxyterminal VSV-G epitope (Kovalenko et al., 2000) , were initially used to investigate the eects of Matrigel TM on DEP-1 activity. DEP-1 expressing or non-expressing X23 cells were taken to suspension and equal number of cells were incubated with either a 1 : 1 mix of Matrigel TM and culture medium or culture medium alone. After stimulation, fractions of lysates were subjected to anti-VSV-G immunoprecipitations and PTP activity in immunoprecipitates was determined. As shown in Figure 1a stimulation with Matrigel TM increased DEP-1 activity more than twofold. No increase in the unspeci®cally recovered PTP activity from non-induced cells was observed. Analysis of immunoprecipitates by anti-DEP-1 immunoblotting demonstrated that equal amounts of DEP-1 was recovered from unstimulated cells and cells stimulated with Matrigel TM (Figure 1b) , suggesting that the change in DEP-1 activity after Matrigel TM stimulation re¯ects an increase in speci®c activity of DEP-1.
To con®rm that Matrigel e. PAE cells with a VSV-G tagged form of human DEP-1 expressed under the control of a tTA regulated promotor, and induction of DEP-1 expression were performed as described previously (Kovalenko et al., 2000) . Prior to stimulation cells were brought to suspension by 10 min incubation in 378C with versene (137 mM NaCl, 2.7 mM KCl, 1.42 mM KH 2 PO 4 8.42 mM Na 2 HPO 4 and 1.0 mM EDTA). After pelleting by centrifugation (1000 g, 4 min) cells were resuspended in a small volume of DMEM or a 1 : 1 mix of DMEM and Matrigel TM (Becton-Dickinson) and incubated for 1 h at 48C. The samples were diluted ten times with DMEM and an aliquot of the sample was taken for cell counting and staining of cells with trypan blue before pelleting of cells by centrifugation (1000 g, 4 min). The cells were lysed in lysis buer containing 0.5% Triton X-100, 0.5% Na-deoxycholate, 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM EDTA, 30 mM Na 2 P 2 O 7 , 1% Trasylol, 1 mM phenyl methyl sulfonyl¯uoride (PMSF) and 2 mM dithiothreitol (DTT). Lysates were clari®ed by centrifugation (16 000 g, 15 min). DEP-1 was immunoprecipitated from X23 cells using anti-VSV-G mouse monoclonal antibody (Sigma) and rabbit anti-mouse IgG antibody (Dako). Immunocomplexes were collected on Protein-A-Sepharose beads and washed three times with lysis buer and once in PTP assay buer (20 mM Imidazole, 0.1 mg/ml bovine serum albumin and 10 mM DTT). For the PTP assay Src optimal peptide (Songyang Z et al., 1995) was radioactivelly labeled at its tyrosine residue using g-32 P-ATP and recombinant human c-Src (Upstate Biotechnology Incorporated). Assays were performed with an initial phosphotyrosine concentration of 3 mM in a volume of 60 ml, reactions were terminated after 6 min at 308C by addition of 290 ml charcoal mixture (Streuli et al., 1989) . After centrifugation (16 000 g, 2 min), free phosphate in the supernatant was measured by scintillation counting. Assays were performed with duplicates of samples. (Figure 2 ). PTP assays of control (mIgG) immunoprecipitations were also performed and showed no change in activity after stimulation. The changes in DEP-1 activity was not caused by Matrigel induced changes in DEP-1 expression levels (data not shown).
From these experiments we conclude that Matrigel TM contains a component(s) with the ability to directly or indirectly modulate the speci®c activity of DEP-1.
To investigate whether the enhancement of DEP-1 activity after Matrigel TM stimulation is due to direct interaction of Matrigel TM component(s) with DEP-1, stimulation of immunoprecipitated DEP-1 was performed. Protein-A-Sepharose immobilized anti-VSV-G immunoprecipitates from DEP-1 expressing or nonexpressing X23 cells were divided and incubated with either a 1 : 1 mix of Matrigel TM and culture medium or culture medium alone. Stimulation of immunoprecipitated DEP-1 with Matrigel TM led to an enhancement of the PTP activity, in contrast no increase was observed in the unspeci®cally recovered PTP activity from noninduced cells (Figure 3a) . Analysis of anti-VSV-G immunoprecipitates by immunoblotting with anti-DEP-1 and anti-VSV-G antibodies, recognizing the extracellular domain and the carboxy-terminal VSV-G epitope of DEP-1, respectively, showed that Matrigel TM stimulation did neither aect the recovery of DEP-1 nor induce proteolytic cleavage of DEP-1 (Figure 3b ). Since no detectable PTP activity was recovered in immunoprecipitates of a catalytically inactive form of DEP-1 (data not shown), we can exclude the possibility that the eect of Matrigel occurs through modulation of a PTP associating with DEP-1. The experiments presented in Figure 3 thus strongly suggest that the agonistic eect of Matrigel TM on DEP-1 speci®c activity occurs through direct interactions between a Matrigel TM component(s) and DEP-1. Two experiments designed to investigate if the Matrigel TM DEP-1 agonist is interacting with the extracellular domain of DEP-1 were performed. In the ®rst experiment the eect of preincubation of Matrigel TM with a recombinant GST-fusion form of the DEP-1 extracellular domain was investigated. As a control for unspeci®c eects caused by the GSTdomain, a recombinant GST-fusion form of the PDGF b-receptor was used. Preincubation of Matrigel TM with DEP-1 extracellular domain consistently reduced the Matrigel TM induced increase in DEP-1 speci®c activity (Figure 4a ). Although some inhibitory eects of the PDGFR-b-ECD-GST protein was observed, this eect was in all experiments lesser than the inhibitory eect of the DEP-1 extracellular domain. Analysis by immunoblotting of DEP-1 levels after the various stimulation con®rmed that equal amounts of DEP-1 was analysed in PTP assays (Figure 4b) . Preincubation of the control medium with the recombinant GSTfusion form of the DEP-1 extracellular domain did not aect DEP-1 speci®c activity (data not shown).
In the second experiment DECD-DEP-1, an aminoterminally truncated form of DEP-1 lacking the major part of the extracellular domain of DEP-1, was used to evaluate the role of the extracellular domain of DEP-1 for Matrigel TM stimulation of speci®c activity. Comparision of transiently expressed and immunoprecipitated DEP-1 and DECD-DEP-1 did not indicate any dierences in speci®c activity between DEP-1 and DECD-DEP-1 (data not shown). DEP-1 and DECD-DEP-1 were transiently expressed in COS cells, recovered by immunoprecipitations and subjected to stimulation with either a 1 : 1 mix of Matrigel TM and culture medium or culture medium only ( Figure 4c ). As in previous experiments wild-type DEP-1 was activated by Matrigel TM stimulation. In contrast, Matrigel TM stimulation did not increase the activity of DECD-DEP-1. Analysis by immunoblotting of immunoprecipitated DEP-1 and DECD-DEP-1 con®rmed that equal amounts of proteins were used for control stimulation and for Matrigel TM stimulation (Figure 4d ). Together the experiments presented in Figure 4 provide strong support for the notion that the Matrigel TM component(s) responsible for alterations of DEP-1 speci®c activity exerts its eects through interaction with the extracellular domain of DEP-1.
Molecular mechanisms proposed to regulate the speci®c activity of rPTPs include serine/threonine TM enhances DEP-1 activity. HaCaT cells were stimulated with a 1 : 1 mix of Matrigel TM and culture medium (+stimulation) or culture medium only (7stimulation). Cell lysates were subjected to immunoprecipitations with a mouse IgG fraction (ctrl.) or anti-DEP-1 monoclonal antibody (anti-DEP-1) and rabbit anti-mouse IgG. PTP activity recovered in DEP-1 immunoprecipitates from unstimulated HaCaT cells was set to 100% and corresponds to dephosphorylation of 8% of added substrate. Error bars indicate s.e.m. The experiment was performed ®ve times. Materials and methods: HaCaT cells, human keratinocytes, were cultured in DMEM supplemented with 10% fetal calf serum, 2 mM glutamine, 1000 U/1 penicillin and 1 mg/l streptomycin. Stimulation with Matrigel, preparation of cell lysates and PTP assays was performed as in Figure 1 . DEP-1 was immunoprecipitated with the mouse monoclonal antibody 143.41 phosphorylation (Wang et al., 1999) , tyrosine phosphorylation (Stover et al., 1991; Stover and Walsh, 1994) , as well as dimerization (Bilwes et al., 1996; Jiang et al., 1999; Majeti et al., 1998) . Whether the DEP-1 agonist(s) in Matrigel TM acts by any of these mechanisms remain presently unknown and merits further investigations.
Although our study does not address the biological consequences of Matrigel TM mediated stimulation of DEP-1 activity, the identi®cation of Matrigel TM as a source of an agonistic DEP-1 ligand should aid in future studies aiming at identifying cellular processes regulated by DEP-1. The expression of DEP-1 in many epithelial cells with glandular dierentiation (Autschbach et al., 1999) , which are juxtaposed to extracellular-rich basement membranes suggests that regulated expression of a DEP-1 agonist in extracellular matrix constitutes a biological control mechanism.
Matrigel TM is a preparation of extracellular matrix proteins secreted by Englebreth ± Holm ± Swarm mouse sarcoma. Among the known components of matrigel Analysis of DEP-1 immunoprecipitated from X23 cells were performed as described in Figure 3 . DEP-ECD-GST is a recombinant protein, puri®ed from the conditioned media of transfected CHO cells, composed of the extracellular domain of DEP-1 and a carboxy-terminal GST-domain. The expression and puri®cation of DEP-ECD-GST will be described in detail elsewhere. The recombinant GST-fusion form of the PDGF b-receptor extracellular domain have been described earlier (LeppaÈ nen et al., 2000) . The cDNA encoding human carboxy-terminally HA-tagged DEP-1 was generated by insertion, through site-directed mutagenesis, of an MscI restriction site spanning the stop codon of DEP-1. The MscI site was used for ligation with a fragment encoding three consecutive HA-epitopes followed by a stop codon. The cDNA encoding HA-tagged DEP-1 was subsequently inserted as an Eco RI/Eco RI insert into the pSV7d expression vector (Truett et al., 1985) . The DECD-DEP-1 pcDNA3 plasmid encodes a protein composed of the IgG heavy chain signal sequence followed by amino acid residues 895 ± 1336 of DEP-1 and carboxy-terminal HAepitopes. The construct was generated after introduction, by site-directed mutagenesis, of a BamHI restriction site spanning codons 893 and 894 of HA-tagged DEP-1. COS cells were transfected using standard calcium phosphate procedure. Transiently expressed HA-tagged DEP-1 and DECD-DEP-1 was recovered by immunoprecipitation with a polyclonal anti-HA rabbit antiserum, a kind gift from Lars RoÈ nnstrand, Ludwig Institute for Cancer Research (Uppsala, Sweden). Immunoblotting of HA-tagged DEP-1 and D-ECD-DEP-1 was performed with a monoclonal HA-antibody (12CA5, Boehringer ± Mannheim). Immunoprecipitations, Matrigel are laminin, collagen IV and entactin. In preliminary studies we have not obtained any evidence that laminin or collagen IV exerts DEP-1 agonistic activity (data not shown). The puri®cation and identi®cation of the DEP-1 agonist(s) in Matrigel TM represent an obvious goal for future studies.
In conclusion, our experiments demonstrate that Matrigel TM contains a DEP-1 agonist that exerts its eect through interactions with the DEP-1 extracellular domain. Our experiments provide the ®rst evidence of upregulation of the speci®c activity of a rPTP by an extracellular ligand. We expect that our ®ndings, together with the recent demonstration of pleiotrophin as an extracellular PTPb/z antagonist (Meng et al., 2000) , will stimulate additional studies addressing the possibility that other rPTPs also are regulated by extracellular agonists or antagonists.
